Acadia redesigns study on Parkinson's psychosis drug
12:08 EDT 13 Jul 2012 | Reuters
(Reuters) - Acadia Pharmaceuticals Inc said it redesigned an ongoing late-stage study on its experimental anti-psychotic drug for Parkinson's disease patients, and that it plans to conduct an identical study to win regulatory approval.
Original Article: Acadia redesigns study on Parkinson's psychosis drug
More From BioPortfolio on "Acadia redesigns study on Parkinson's psychosis drug"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
